The human plasma-derived polyvalent IgM/IgA-enriched Ig preparation trimodulin (≈23% IgM, ≈21% IgA, ≈56% IgG), is currently in development for the treatment of severe infections in adults, including severe community-acquired pneumonia (sCAP) and severe coronavirus disease 2019 (COVID-19). Here, CD40LG is linked to COVID-19.